NeuBase Therapeutics
Pittsburgh, US · Delaware corporation
Founders & leadership
DS
Dietrich StephanFounder
TB
Todd BranningExecutive
SB
Sam BackenrothExecutive
IT
Irach TaraporewalaExecutive
ER
Eric RichmanNamed on SEC filing
FP
Franklyn PrendergastNamed on SEC filing
GM
Gerald McDougallNamed on SEC filing
DG
Dov GoldsteinNamed on SEC filing
Board
OH
Orin HirschmanBoard director
JA
June AlmenoffBoard director
TR
Thomas RiedhammerBoard director
IG
Ira GreensteinBoard director
Reported raises · per SEC filings
Form D private placements$15.8M disclosed across 4 rounds · 2013–2023
▶$5MraisedJul 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric RichmanDirector
- Todd BranningExecutive Officer
- Dietrich StephanExecutive Officer, Director
- Franklyn PrendergastDirector
- Gerald McDougallDirector
- Dov GoldsteinDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $482.4K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedDec 2014 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedDec 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Irach TaraporewalaExecutive Officer, Director
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- June AlmenoffDirector
- Sam BackenrothExecutive Officer
- Ira GreensteinDirector
- Offering amount
- $50K
- Amount sold
- $50K
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.2MraisedJun 2014 · 1 investors · BiotechnologyRule 506(b)
▶$10.2MraisedJun 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sam BackenrothExecutive Officer
- June AlmenoffDirector
- Ira GreensteinDirector
- Irach TaraporewalaExecutive Officer, Director
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- Offering amount
- $25.2M
- Amount sold
- $10.2M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$569.6KraisedJan 2014 · 3 investors · BiotechnologyRule 506(b)
▶$569.6KraisedJan 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- June AlmenoffDirector
- Orin HirschmanDirector
- Thomas RiedhammerDirector
- Ira GreensteinDirector
- Sam BackenrothExecutive Officer
- Irach TaraporewalaExecutive Officer, Director
- Offering amount
- $569.6K
- Amount sold
- $569.6K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded NeuBase Therapeutics?
- NeuBase Therapeutics was founded by Dietrich Stephan.
- How much funding has NeuBase Therapeutics raised?
- NeuBase Therapeutics has disclosed $15.8M raised across 4 rounds.
- Where is NeuBase Therapeutics headquartered?
- NeuBase Therapeutics is headquartered in Pittsburgh, US.